Lipocine Announces Late Breaking Oral Presentation Of Data From The Phase 2 Study Of LPCN 1148 At EASL Congress 2024
Lipocine Announces Late Breaking Oral Presentation Of Data From The Phase 2 Study Of LPCN 1148 At EASL Congress 2024
Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company, today announced that data from the Phase 2 study of LPCN 1148 has been selected for a late breaking oral presentation at the European Association for the Study of Liver ("EASL") Congress, to take place June 5 to 8, 2024 in Milan, Italy.
生物制药公司Lipocine Inc.（纳斯达克股票代码：LPCN）今天宣布，LPCN 1148的2期研究数据已被选中作为将于2024年6月5日至8日在意大利米兰举行的欧洲肝脏研究协会（“EASL”）大会的晚间口头报告。
Presentation Details
演示详情
| Title | Intervention with oral LPCN 1148 improves sarcopenia and hepatic encephalopathy ("HE") in patients with cirrhosis: a 52-week phase 2 randomized clinical trial |
| Presenter: | Dr. Arun J. Sanyal, MD, Director, Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, Virginia Commonwealth University |
| Session Title: | Late Breaker |
| Session Date and Time: | Saturday, 8 June, 14:00 - 15:30 CEST |
| Presentation Time: | 15.15 CEST |
| Location | Gold Room |
| Abstract Number: | LP139 |
| 标题 | 口服 LPCN 1148 干预可改善肝硬化患者的肌肉减少症和肝性脑病（“HE”）：一项为期 52 周的 2 期随机临床试验 |
| 演示者： | Arun J. Sanyal博士，医学博士，弗吉尼亚联邦大学斯特拉维茨-桑亚尔肝病与代谢健康研究所所长 |
| 会议标题： | 后期破解者 |
| 会话日期和时间： | 6月8日星期六，欧洲中部标准时间 14:00-15:30 |
| 演示时间： | 15.15 CEST |
| 地点 | 金色房间 |
| 摘要编号： | LP139 |
About LPCN 1148
关于 LPCN 1148
Lipocine is currently evaluating LPCN 1148 comprising testosterone laurate ("TL") for the management of decompensated cirrhosis. The Company believes LPCN 1148 targets unmet needs for patients with cirrhosis including improvements in sarcopenia and quality of life, prevention or reduction in the occurrence of decompensation events such as HE, and improvement in post liver transplant outcomes, survival, and costs.
Lipocine目前正在评估含有月桂酸睾酮（“TL”）的LPCN 1148，用于治疗失代偿性肝硬化。该公司认为，LPCN 1148的目标是肝硬化患者未得到满足的需求，包括改善肌肉减少症和生活质量，预防或减少HE等失代偿事件的发生，以及改善肝移植后的结果、存活率和成本。